Pediatric Nephrology

, Volume 20, Issue 12, pp 1786–1793 | Cite as

Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis

  • Ranjan Dohil
  • Meredith Fidler
  • Bruce Barshop
  • Robert Newbury
  • Zachary Sellers
  • Reena Deutsch
  • Jerry Schneider
Original Article
First Online:
Received:
Revised:
Accepted:

Abstract

Oral cysteamine therapy prevents natural disease progression in children with cystinosis, but it may cause severe gastrointestinal (GI) symptoms through gastric acid-hypersecretion. The purpose of this study was to assess the value of esomeprazole in controlling cysteamine-induced acid-hypersecretion and GI symptoms in children with cystinosis. Subjects underwent upper GI endoscopy and biopsy, serum gastrin and cysteamine measurements as well as acid secretion studies (basal, maximal and peak acid output, BAO, MAO, PAO) before and during esomeprazole therapy. A symptom score (maximum 14 points) was devised to monitor symptoms. Twelve children (mean age 5.8 years) were studied. Cysteamine ingestion resulted in mean MAO and PAO significantly higher than mean BAO, both before and during esomeprazole therapy. PAO was usually within 60 min of cysteamine ingestion. Esomeprazole therapy significantly reduced MAO (P<0.01) and PAO (P<0.01). The mean symptom score fell from 6.4 to 0.7 (P<0.0001) during esomeprazole therapy. The mean final dose of esomeprazole was 1.7 mg/kg per day (range 0.7 mg/kg per day to 2.75 mg/kg per day). Plasma cysteamine levels were not affected by acid-suppression therapy. One child had multi-nucleated parietal cells. Cysteamine-induced gastric acid-hypersecretion and GI symptoms are dramatically reduced with esomeprazole therapy. Esomeprazole does not alter cysteamine absorption and is very well tolerated in children.

Keywords

Esomeprazole Gastric acid secretion Cysteamine Serum gastrin Symptom score Upper gastrointestinal endoscopy Multi-nucleated parietal cells 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

Support was provided by AstraZeneca, Wilmington, Delaware, USA and National Institute of Health grant MO1RR00827.

References

  1. 1.
    Gahl WA, Thoene JG, Schneider JA (2002) Cystinosis. N Engl J Med 347:111–121CrossRefPubMedGoogle Scholar
  2. 2.
    Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schlesselman JJ, Corden BJ, Schneider JA (1987) Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 316:971–977PubMedGoogle Scholar
  3. 3.
    Markello TC, Bernardini IM, Gahl WA (1993) Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 328:1157–1162CrossRefPubMedGoogle Scholar
  4. 4.
    Elenberg E, Norling LL, Kleinman RE, Ingelfinger JR (1998) Feeding problems in cystinosis. Pediatr Nephrol 12:365–370CrossRefPubMedGoogle Scholar
  5. 5.
    Dohil R, Newbury RO, Sellers ZM, Deutsch R, Schneider JA (2003) The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J Pediatr 143:224–230CrossRefPubMedGoogle Scholar
  6. 6.
    Pfeiffer DC, Pfeiffer CJ, Szabo S (1987) Development of cysteamine-induced ultrastructural surface changes on duodenal mucosa. Lab Invest 56:444–450PubMedGoogle Scholar
  7. 7.
    Kirkegaard P, Poulsen SS, Loud FB, Halse C, Christiansen J (1980) Cysteamine-induced duodenal ulcer and acid secretion in the rat. Scand J Gastroenterol 15:621–624PubMedGoogle Scholar
  8. 8.
    Poulsen SS, Olsen PS, Kirkegaard P (1985) Healing of cysteamine-induced duodenal ulcers in the rat. Dig Dis Sci 30:161–167CrossRefPubMedGoogle Scholar
  9. 9.
    Wenner WJ, Murphy JL (1997) The effects of cysteamine on the upper gastrointestinal tract of children with cystinosis. Pediatr Nephrol 11:600–603CrossRefPubMedGoogle Scholar
  10. 10.
    Lindstedt G, Olbe L, Kilander AF, Armbrecht U, Jagenburg R, Runsteen D, Lundberg PA (1985) Analytical and clinical evaluation of a radioimmunoassay for gastrin. Clin Chem 31:76–82PubMedGoogle Scholar
  11. 11.
    Guan X HG, Dwivedi C, Matthees DP (2003) A simultaneous liquid chromatography/mass spectrometric assay of glutathione, cysteine, homocysteine and their disulfides in biological samples. J Pharm Biomed Anal 31:251–261CrossRefPubMedGoogle Scholar
  12. 12.
    Isenberg JI, Grossman MI, Maxwell V, Walsh JH (1975) Increased sensitivity to stimulation of acid secretion by pentagastrin in duodenal ulcer. J Clin Invest 5:330–337Google Scholar
  13. 13.
    Carpenter HA, Talley NJ (1995) Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology108:917–924Google Scholar
  14. 14.
    Dohil R, Hassall E, Jevon G, Dimmick J (1999) Gastritis and gastropathy of childhood. J Pediatr Gastroenterol Nutr 29:378–394CrossRefPubMedGoogle Scholar
  15. 15.
    Gillett P, Hassall E (2000) Pediatric gastrointestinal mucosal biopsy. Special considerations in children. Gastrointest Endosc Clin N Am 10:669–712PubMedGoogle Scholar
  16. 16.
    Schwartz GJ HG, Edelman CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMedGoogle Scholar
  17. 17.
    Selye H, Szabo S (1973) Experimental model for production of perforating duodenal ulcers by cysteamine in the rat. Nature 244:458–459PubMedGoogle Scholar
  18. 18.
    Ishii Y, Fujii Y, Homma M (1976) Gastric acid stimulating action of cysteamine in the rat. Eur J Pharmacol 36:331–336CrossRefPubMedGoogle Scholar
  19. 19.
    Lichtenberger LM, Szabo S, Trier JS (1977) Duodenal ulcerogens, cysteamine and propionitrile, stimulate serum gastrin levels in the rat. Gastroenterology 73:1305–1308PubMedGoogle Scholar
  20. 20.
    Lichtenberger LM, Szabo S, Reynolds ES (1977) Gastric emptying in the rat is inhibited by the duodenal ulcerogens, cysteamine and propionitrile. Gastroenterology 73:1072–1076PubMedGoogle Scholar
  21. 21.
    Kirkegaard P, Poulsen SS, Halse C, Loud FB, Skov Olsen P, Christiansen J (1981) The effect of cysteamine on the Brunner gland secretion in the rat. Scand J Gastroenterol 16:93–96PubMedGoogle Scholar
  22. 22.
    Poulsen SS, Kirkegaard P, Skov Olsen P, Christiansen J (1981) Brunner’s glands of the rat during cysteamine ulceration. Scand J Gastroenterol 16:459–464PubMedGoogle Scholar
  23. 23.
    Kimonis VE, Troendle J, Rose SR, Yang ML, Markello TC, Gahl WA (1995) Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab 80:3257–3261CrossRefPubMedGoogle Scholar
  24. 24.
    Miner P Jr KP, Chen Y, Sostek M (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98:2616–2620PubMedGoogle Scholar

Copyright information

© IPNA 2005

Authors and Affiliations

  • Ranjan Dohil
    • 1
    • 2
  • Meredith Fidler
    • 2
  • Bruce Barshop
    • 2
  • Robert Newbury
    • 3
  • Zachary Sellers
    • 4
  • Reena Deutsch
    • 2
    • 5
  • Jerry Schneider
    • 2
  1. 1.UCSD Medical CenterSan DiegoUSA
  2. 2.Department of PediatricsUniversity of CaliforniaSan DiegoUSA
  3. 3.Department of PathologyChildren’s Hospital and Health CenterSan DiegoUSA
  4. 4.Department of MedicineUniversity of CaliforniaSan DiegoUSA
  5. 5.Department of Family and Preventive MedicineUniversity of CaliforniaSan DiegoUSA

Personalised recommendations